Crisugabalin

Summary

Crisugabalin (CHEMBL5314958) is a phase-3 clinical-stage small molecule; indicated across 6 conditions including neuralgia and herpes zoster.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 6 conditions
• Clinical trials: 7
• Chemistry: 209.28 Da · C12H19NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314958
Name	Crisugabalin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	139300919
Molecular formula	C12H19NO2
Molecular weight	209.28
InChIKey	WCEFMBSFXJUREW-LIJGXYGRSA-N

SMILES: C1C[C@@H]2[C@@H]3C[C@H]1C[C@@H]3[C@@]2(CC(=O)O)CN

IUPAC name: 2-[(1S,2S,3R,6S,8S)-2-(aminomethyl)-2-tricyclo[4.2.1.03,8]nonanyl]acetic acid

Also known as: Crisugabalin, Crisugabalina, Crisugabaline, HSK-16149, Hsk16149, CRISUGABALIN

Patent coverage: 6 distinct patent families (13 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuralgia	3	MONDO:0021667	EFO:0005762
herpes zoster	2	MONDO:0005609	EFO:0006510
kidney disorder	1	MONDO:0005240	EFO:0003086
diabetic neuropathy	1	MONDO:0006626	EFO:1000783

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2	2
PHASE4	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07483398	PHASE4	ACTIVE_NOT_RECRUITING	RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson’s Disease
NCT06766916	PHASE2	RECRUITING	Crisugabalin for Radiotherapy-Related Neuropathic Pain
NCT06007066	PHASE2	COMPLETED	HSK16149 for Perioperative Analgesia in Orthopedic Surgery
NCT07453862	PHASE1	RECRUITING	Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety
NCT04841720	PHASE1	UNKNOWN	A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets
NCT05916573	PHASE1	COMPLETED	A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment
NCT07196657	Not specified	RECRUITING	The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).